22.04
前日終値:
$22.44
開ける:
$22.49
24時間の取引高:
36.84M
Relative Volume:
0.81
時価総額:
$125.00B
収益:
$63.63B
当期純損益:
$8.03B
株価収益率:
15.63
EPS:
1.41
ネットキャッシュフロー:
$9.84B
1週間 パフォーマンス:
-2.00%
1か月 パフォーマンス:
-14.31%
6か月 パフォーマンス:
-25.72%
1年 パフォーマンス:
-14.21%
Pfizer Inc Stock (PFE) Company Profile
PFE を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
![]()
PFE
Pfizer Inc
|
22.04 | 125.00B | 63.63B | 8.03B | 9.84B | 1.41 |
![]()
LLY
Lilly Eli Co
|
734.90 | 660.07B | 45.04B | 10.59B | 414.30M | 11.71 |
![]()
JNJ
Johnson Johnson
|
153.91 | 344.63B | 89.33B | 21.81B | 18.06B | 8.99 |
![]()
ABBV
Abbvie Inc
|
171.68 | 303.70B | 56.33B | 4.28B | 17.83B | 2.40 |
![]()
NVO
Novo Nordisk Adr
|
62.88 | 279.13B | 42.09B | 14.65B | 10.11B | 3.2833 |
![]()
NVS
Novartis Ag Adr
|
109.58 | 216.43B | 51.72B | 11.94B | 13.81B | 5.88 |
Pfizer Inc Stock (PFE) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2024-12-10 | 再開されました | BofA Securities | Neutral |
2024-11-15 | 開始されました | Wolfe Research | Underperform |
2024-10-25 | 再開されました | Citigroup | Neutral |
2024-10-17 | 開始されました | Bernstein | Mkt Perform |
2024-08-07 | アップグレード | Daiwa Securities | Neutral → Outperform |
2024-03-22 | ダウングレード | Argus | Buy → Hold |
2024-02-23 | 開始されました | Guggenheim | Buy |
2024-01-04 | ダウングレード | TD Cowen | Outperform → Market Perform |
2023-10-20 | 再開されました | UBS | Neutral |
2023-10-16 | アップグレード | Jefferies | Hold → Buy |
2023-07-17 | 繰り返されました | JP Morgan | Neutral |
2023-07-14 | 開始されました | HSBC Securities | Buy |
2023-06-29 | ダウングレード | Credit Suisse | Outperform → Neutral |
2023-05-11 | ダウングレード | Daiwa Securities | Outperform → Neutral |
2023-03-06 | 開始されました | Jefferies | Hold |
2023-02-07 | アップグレード | Daiwa Securities | Neutral → Outperform |
2023-01-26 | ダウングレード | UBS | Buy → Neutral |
2023-01-17 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
2023-01-04 | ダウングレード | BofA Securities | Buy → Neutral |
2022-12-13 | アップグレード | Goldman | Neutral → Buy |
2022-11-18 | 開始されました | Credit Suisse | Outperform |
2022-05-23 | 開始されました | SVB Leerink | Mkt Perform |
2022-04-06 | 再開されました | Morgan Stanley | Equal-Weight |
2022-01-05 | アップグレード | BofA Securities | Neutral → Buy |
2022-01-03 | 繰り返されました | Bernstein | Mkt Perform |
2021-12-20 | 繰り返されました | Cowen | Outperform |
2021-12-17 | 開始されました | Goldman | Neutral |
2021-12-13 | アップグレード | UBS | Neutral → Buy |
2021-12-09 | 開始されました | Wells Fargo | Overweight |
2021-11-19 | 開始されました | BMO Capital Markets | Outperform |
2021-07-27 | 再開されました | Truist | Buy |
2021-05-06 | ダウングレード | Mizuho | Buy → Neutral |
2021-04-07 | 再開されました | RBC Capital Mkts | Sector Perform |
2021-02-04 | アップグレード | DZ Bank | Hold → Buy |
2020-12-16 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
2020-11-19 | 再開されました | Goldman | Neutral |
2020-11-10 | 再開されました | Bernstein | Mkt Perform |
2020-10-12 | ダウングレード | Atlantic Equities | Overweight → Neutral |
2020-09-29 | 開始されました | Berenberg | Hold |
2020-06-16 | 開始されました | SVB Leerink | Mkt Perform |
2020-02-27 | 開始されました | Barclays | Equal Weight |
2020-02-27 | アップグレード | Standpoint Research | Hold → Buy |
2020-02-06 | 開始されました | Mizuho | Buy |
2020-01-07 | 開始されました | RBC Capital Mkts | Outperform |
2019-10-17 | 再開されました | BofA/Merrill | Neutral |
2019-07-30 | ダウングレード | BofA/Merrill | Buy → Neutral |
2019-07-30 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
2019-06-04 | 再開されました | Morgan Stanley | Overweight |
2019-02-20 | 再開されました | Citigroup | Neutral |
2019-01-31 | アップグレード | Argus | Hold → Buy |
2019-01-31 | アップグレード | Credit Suisse | Neutral → Outperform |
2019-01-23 | ダウングレード | UBS | Buy → Neutral |
2018-12-11 | ダウングレード | JP Morgan | Overweight → Neutral |
2018-11-01 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
すべてを表示
Pfizer Inc (PFE) 最新ニュース
Henlius In David Versus Goliath Race With Pfizer For First PD-L1 ADC - insights.citeline.com
Pfizer: Risks Priced In, Buy The Exceptional Valuation And Yield - Seeking Alpha
Lobbying Update: $20,000 of PFIZER INC lobbying was just disclosed - Nasdaq
GSK, Pfizer Zantac Appeal Gets Tough Questions From Some Delaware Judges - Bloomberg.com
Pfizer Says US CDC Panel Votes to Expand Recommendation for RSV Vaccine - MarketScreener
Pfizer gets ACIP backing as it votes to expand RSV vaccine recommendation - Seeking Alpha
ACIP Votes to Expand Recommendation for Pfizer’s RSV Vaccine ABRYSVO - Business Wire
Pfizer: Tasty 7% Yield (NYSE:PFE) - Seeking Alpha
What You Need to Know Ahead of Pfizer's Earnings Release - Nasdaq
Empyema Market Deep Research Report with Forecast by 2032 | Pfizer Inc.,Merck & Co., Inc.,GlaxoSmithKline plc - openPR.com
Stomach Cancer Drugs Market Witness Significant Growth by 2025-2032 | Pfizer Inc., Eli Lilly and Company - openPR.com
Tariff Turmoil, FDA’s Future, Pfizer’s Obesity Setback and CEO Salaries Revealed - BioSpace
Neuropathic Pain Market Detailed In New Research Report 2025 | - openPR.com
Why Pfizer Stock Topped the Market on Tuesday - Yahoo Finance
Will Pfizer approach Viking Therapeutics with a buyout proposal? - TradingView
Novavax Covid Vaccine Shows Milder Side Effects Than Pfizer-BioNTech's Shot: Study - Benzinga
Viking Therapeutics' VK2735 Candidate Likely Boosted By Pfizer's Woes (NASDAQ:VKTX) - Seeking Alpha
Pfizer Halts Obesity Pill Development Amid Safety Concerns - Zacks Investment Research
Bernstein reiterates Pfizer stock with $30 target post-drug axe - Investing.com
Bernstein reiterates Pfizer stock with $30 target post-drug axe By Investing.com - Investing.com India
TD Cowen Remains a Hold on Pfizer (PFE) - The Globe and Mail
Pfizer (PFE) Gets a Hold from Bernstein - The Globe and Mail
BofA keeps Neutral on Pfizer after danuglipron failure as core thesis unchanged - Yahoo Finance
Pfizer Ends Testing of Obesity Pill After Possible Liver Injury - El Paso Inc.
Smaller obesity drugmakers jump after Pfizer scraps weight-loss pill - Yahoo Finance
What You Need To Know Ahead Of Pfizer's Earnings Release - Barchart.com
Is High-Yield Pfizer Stock Still a Buy After Scrapping Its Weight-Loss Pill? - MSN
Is High-Yield Pfizer Stock Still a Buy After Scrapping Its Weight-Loss Pill? - The Motley Fool
Pfizer scraps weight loss candidate after trial setback: What it means for the future of oral obesity drugs - munsifdaily.com
Pfizer Halts Oral GLP-1 Drug Danuglipron Development Amid Liver Safety Concerns - geneonline.com
Pfizer (PFE) Abandons Obesity Drug Trial Due to Safety Concerns - GuruFocus
Pfizer (PFE) Halts Trial of GLP-1 Pill Due to Safety Concerns - GuruFocus
Why Pfizer scrapped obesity pill development: Weight-loss drug market shares explored - financialexpress.com
Pfizer Ends Development of Its Obesity Pill - Time Magazine
Pfizer ends development of potential pill obesity treatment - CNN
Pfizer to no longer develop weight loss pill - The San Joaquin Valley Sun
Pfizer hits setback in obesity drug race as GLP-1 trial halts - Yahoo Finance
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Cerevel Therapeutics Holdings, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
Health Care Up on Defensive DemandHealth Care Roundup - MarketScreener
Obesity Drug Developers Rise on M&A Hopes After Pfizer Setback - Bloomberg.com
Pfizer halts development of weight loss pill after liver injury report - KFXL
Pfizer: Discontinuation of Obesity Drug Candidate Danuglipron Has No Effect on Our Valuation - Morningstar
Pfizer Abandons Obesity Pill After Liver Injury in Setback - Bloomberg
Pfizer Halts Development of Oral Obesity Drug Danuglipron After Safety Review - Mega Doctor News
Pfizer ends development of weight-loss pill after patient's liver injury - upi.com
Thoracic Radiculopathy Market Is Booming Worldwide 2025-2032 | Pfizer Inc.,Johnson Johnson (DePuy Synthes) - openPR.com
Is Pfizer Stock (PFE) Worth Buying After Its Weight Loss Pill Failure? - The Globe and Mail
Pfizer’s Danuglipron Is Done, Sparking M&A Speculation - insights.citeline.com
Pfizer: Discontinuation of Obesity Drug Candidate Danuglipron Has No Effect on Our $42 Valuation - Morningstar
PFIZER INC : Receives a Buy rating from Jefferies - MarketScreener
Pfizer, Inc. (PFE) Stock Forecasts - Yahoo Finance
Pfizer Inc (PFE) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):